Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|KIT V560D KIT T670I||Advanced Solid Tumor||resistant||Flumatinib||Preclinical - Cell culture||Actionable||In a preclinical study, transformed cells co-expressing KIT V560D and KIT T670I were resistant to Flumatinib in culture (PMID: 24205792).||24205792|
|KIT V560D KIT T670I||Advanced Solid Tumor||sensitive||Motesanib Diphosphate||Preclinical - Cell culture||Actionable||In a preclinical study, Motesanib (AMG 706) inhibited KIT phosphorylation and growth of cells expressing a KIT V560D/T670I double mutation in culture (PMID: 20633291).||20633291|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|